Bio networking dayYou are hereAbout BioAlpsPhoto galleryArchives photo galleryBioAlps networking day (part 2)Bio networking day
Find an actor
Journée de l'innovation 201818.10.2018Jeudi 18 octobre, 13h-18h au Centre de l'innovation des HUG Bâtiment Gustave Julliard, 17 rue Alcide-Jentzer 1205...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.